Image
 

Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.

 

 

trial #
trial description
  • SWOG S1001
  • Limited (or early) stage diffuse large B-cell lymphoma is curable in many people, but some still relapse, and some develop side effects after treatment. This study uses a test called PET/CT scan to determine treatment after initial doses of a standard chemotherapy called "R-CHOP" (This is the drugs: doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab). Although all of the drugs used in this study are approved by the Food and Drug Administration (called FDA), the purpose of the study is to give more intensive treatment to patients whose PET/CT scan shows that they are at a greater chance of still having active lymphoma, and to give less intensive treatment to patients whose PET/CT scan shows that they have a smaller chance of still having active lymphoma. In this way, we hope to improve the cure rate for all patients while decreasing the side effects of the treatment.

  • SWOG S1608
  • The purpose of this study is to compare any good and bad effects of using different drugs in combination with an antibody.  An antibody is a protein that can recognize and attack foreign objects (antigens) in the body.  Here, the antibody is obinutuzumab. It is looking for CD20, an antigen that is found on tumor cells.  Two study drugs will be tested in this study: TGR-1202 and lenalidomide.  Each of these study drugs may help the immune system fight cancer.  During the study, you will get either obinutuzumab plus TGR-1202, obinutuzumab plus lenalidomide, or obinutuzumab plus the usual approach treatment for your follicular lymphoma

    The addition of TGR-1202 or lenalidomide could shrink your cancer, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of a study drug should increase the chances of your cancer shrinking by about 45% compared to the usual approach. The antibody (obinutuzumab) and the regular chemotherapy approach are FDA-approved for use in follicular lymphoma, but they aren’t usually used together.  The immune system drug. TGR-1202 is not FDA approved. The immune system drug lenalidomide is FDA approved, but not for follicular lymphoma (your type of cancer).

    Another purpose of this study is to test PET/CT scans, which are a way to take pictures of your type of cancer. The researchers want to use PET/CT scans to help diagnose and monitor your cancer.  PET/CT scans are a part of regular care for your type of cancer.  All of the patients taking part in this study will have PET/CT scans sent to a central PET/CT reviewer.

    Another purpose of this study is to see whether a set of gene mutations (called m7-FLIPI) can predict whether your lymphoma will respond better or worse to the study treatment.  Mutations are permanent changes in your DNA.  The researchers will look for the mutations on your tumor tissue and in tumor cells found in your blood.  All of the patients taking part in this study will have blood and tissue submitted for these gene mutation tests.